Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-11-13 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份解质押及质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the related financing arrangements. There is no financial statement, management discussion, or detailed financial data. The document is relatively short (2975 characters) and focuses on share pledge status and related shareholder information. This fits the definition of a Share Issue/Capital Change announcement, specifically about share pledges and releases, which is categorized under 'SHA'.
2020-11-13 Chinese
中信证券股份有限公司关于闫凯境豁免要约收购天士力医药集团股份有限公司股份的2020年三季度持续督导意见暨持续督导总结报告
M&A Activity Classification · 95% confidence The document is a detailed report from CITIC Securities acting as financial advisor regarding the continuous supervision opinions and summary report for the third quarter of 2020 related to a waiver of a mandatory tender offer obligation for a controlling shareholder transaction involving Tasly Pharmaceutical Group Co., Ltd. It includes detailed information on the transaction, governance, compliance with disclosure obligations, management changes, asset disposal plans, and other related matters. The document contains substantive content and analysis about the transaction and ongoing supervision rather than just an announcement or a brief summary. It is not a typical annual or quarterly financial report, nor is it a simple announcement or certification. The content aligns with a continuous supervision report related to a takeover or acquisition process, which fits best under the category of Transaction in Own Shares (POS) or M&A Activity (TAR). However, since this is about a waiver of a mandatory tender offer and ongoing supervision related to a controlling shareholder's shareholding and related disclosures, it is more aligned with M&A Activity (TAR) filings which cover merger proposals, takeover bids, and related continuous supervision reports. Therefore, the best classification is M&A Activity (TAR).
2020-11-09 Chinese
关于全资子公司药品卡托普利片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its wholly-owned subsidiary's drug passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It details the drug's specifications, approval notice, and potential impact on the company. The document is short (882 characters) and serves as a regulatory announcement about product approval, not a financial report or detailed management discussion. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-09 Chinese
关于子公司产品获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving approval for a clinical trial from the National Medical Products Administration. It details the drug, its development, market context, and risk warnings. The document is short (1598 characters) and serves as a public notice of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it does not mention an attached report or provide a link to a report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial approval, which does not fit other specific categories.
2020-11-04 Chinese
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and references previous announcements about the repurchase plan. The document is short (980 characters) and focuses on the update of share buyback activity rather than presenting financial statements or detailed analysis. This fits the definition of a 'Transaction in Own Shares' filing, which reports on the company's buying back or selling its own shares.
2020-11-03 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020年第三季度报告' which translates to '2020 Third Quarter Report'. It contains detailed financial data including balance sheet items, profit and loss statement items, cash flow statement items, and explanations of significant changes during the quarter. It also includes information about shareholder changes and important corporate events during the quarter. The document is approximately 8900 characters long, which is substantial and contains actual financial statements and analysis, not just an announcement or summary. The content and structure clearly indicate it is a quarterly financial report. Therefore, the appropriate classification is 'Interim / Quarterly Report' (IR). 9M 2020
2020-10-28 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.